Cardiac Resynchronisation Therapy For Patients With Heart Failure
Cardiac Resynchronisation Therapy For Patients With Heart Failure
Cardiac Resynchronisation Therapy For Patients With Heart Failure
&
Summary
Cardiac resynchronisation therapy (CRT) is a non-pharmacological treatment for heart failure. The method resynchronises the contraction of the right and left ventricles, resulting in better cardiac output, thus improving symptoms. This article discusses symptoms, morbidity and mortality of heart failure; potential benefits of CRT to patients quality of life; and the implications of CRT for nursing practice.
Author
Robert Frodsham is senior staff nurse, coronary care unit, Whiston Hospital, Prescot, Liverpool. Email: robert.frodsham@sthkhealth.nhs.uk
Keywords
Cardiovascular system and disorders; Heart disorders: nursing These keywords are based on the subject headings from the British Nursing Index. This article has been subject to double-blind review. For related articles and author guidelines visit our online archive at www.nursing-standard.co.uk and search using the keywords.
HISTORICALLY, DESCRIPTIONS of heart failure exist from ancient Egypt, Greece and India. Ancient Greeks and Romans used the juice of the foxglove (Digitalis purpurea) for sprains and bruises. In the 1700s a tea was brewed from foxglove leaves and used to heal dropsy, a disease in which water accumulates in the body and causes swelling. Modern treatment for heart failure continues to include digoxin. Only a limited understanding of the function of the heart existed until William Harvey described the circulatory system in 1628. Roentgens discovery of X-rays and Einthovens development of electrocardiography in the 1890s led to improvements in the investigation of heart failure (Davis et al 2000). Echocardiography, cardiac catheterisation and nuclear medicine have since improved the diagnosis and investigation of patients with heart failure. This article discusses the symptoms of heart failure and highlights the potential improvements in patients conditions following cardiac resynchronisation therapy (CRT). The implications of CRT for nursing practice are also identified. 46 july 20 :: vol 19 no 45 :: 2005
Heart failure is a major cause of morbidity and mortality in the Western world. In the UK, it is estimated to account for 5 per cent of all hospital admissions: approximately 100,000 each year (National Institute for Health and Clinical Excellence (NICE) 2003). Heart failure affects three to 20 people per 1,000, although this number exceeds 100 per 1,000 in those aged 65 or over (NICE 2003). Heart failure is estimated to occur in 900,000 people per year in the UK and the average age is 76 years (NICE 2003). The incidence of heart failure is increasing because of the ageing population. Advancement in treatments of acute myocardial infarction, such as thrombolysis and emergency angioplasty, leads to survival in patients with impaired left ventricular function. Heart failure population The underlying abnormality for the majority of patients with heart failure in the Western world is impaired left ventricular systolic function secondary to ischaemic cardiomyopathy (Cowie et al 2000). The New York Heart Association (NYHA) classification ranges from class I: no symptoms although left ventricular systolic impairment is evident on echocardiogram to class IV: severe symptoms of breathlessness at rest (Box 1) (Criteria Committee of the New York Heart Association (CCNYHA) 1994). Despite maximal drug treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics and beta-blockers, many patients still experience symptoms of breathlessness on minimal exertion or rest (NYHA classes III and IV). This limitation has a marked impact on quality of life (NICE 2003). Patients with these symptoms will probably experience recurrent and prolonged hospital admissions for episodes of decompensation (acute episodes of worsening symptoms) because of failure of the heart to compensate for the disease and increased loss of independence. Death is most commonly due to ventricular arrhythmia or progressive pump failure as demonstrated in clinical trials. Studies report a mortality of close to 40 per cent within one year of diagnosis and around 10 per cent each year NURSING STANDARD
thereafter (Cowie et al 2000). However, some earlier studies, such as the Hillingdon Heart Study (Cowie et al 1999) were carried out before the widespread introduction of beta-blockers and specialist heart failure nurses. Ventricular dyssynchrony It is estimated that 30 per cent of patients with chronic heart failure have evidence of abnormal interventricular conduction as shown on a 12-lead electrocardiogram (ECG), that is, the QRS complex is greater than 120 milliseconds (Cowie et al 2000); often in the form of left bundle branch block: a type of abnormal interventricular conduction. This abnormal interventricular conduction results in an abnormal activation of the ventricular myocardium, thus causing deranged ventricular contraction, commonly called ventricular dyssynchrony. Typically, the interventricular septum contracts earlier than the delayed contraction of the lateral wall of the left ventricle. In severe cases, dyssynchrony can result in contraction of the septum while the lateral wall is relaxing, and vice versa. If opposing ventricular walls fail to contract together, a sizable proportion of blood is shifted around the left ventricle and is not ejected into the circulation, thereby reducing cardiac output, the amount of blood ejected from the left ventricle in one minute. Dyssynchrony also reduces left ventricular filling time, further reducing the already poor cardiac output. There is also an added risk of intracardiac thrombi. In patients with chronic heart failure and poor systolic function, ventricular dyssychrony further compromises performance and will exacerbate symptoms of heart failure.
FIGURE 1 Dual chamber right-sided cardiac resynchronisation therapy Cardiac resynchronisation therapy leads
Right atrium
Left ventricle
Atrioventricular valve Right ventricle Cardiac resynchronisation therapy (CRT) lead positions used in transvenous CRT. The endocardial leads are positioned in the right atrium and right ventricle, and the left ventricle is paced via a lead, which is passed through the coronary sinus into an epicardial vein on the free wall of the left ventricle
BOX 1 New York Heart Association (NYHA) Scale NYHA I Patients have no limitation on activities and experience no symptoms from ordinary activities, however, there is evidence of left ventricular impairment on echocardiography. Patients experience mild limitation of activity; they are comfortable at rest or with mild exertion. Evidence of mild to moderate left ventricular impairment on echocardiography. Patients experience marked limitation of activity; they are comfortable only at rest. Evidence of moderate to severe left ventricular impairment on echocardiography. Patients confined to bed or chair; even minimal activity causes discomfort and symptoms occur at rest. Evidence of severe left ventricular impairment on echocardiography.
NYHA II
NYHA III
NYHA IV
&
Clinical trials
Several clinical trials have compared CRT with medical treatment alone, such as diuretic and ACE inhibitor therapy. The Multisite Stimulation in Cardiomyopathies (MUSTIC) study (Cazeau et al 2001) and the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) study (Abraham et al 2002), showed improvements in quality of life, exercise tolerance, NYHA class scores, and left ventricle ejection fraction with CRT. The MIRACLE study (Abraham et al 2002) also showed a reduction in hospital admissions for worsening heart failure. At six months the risk of admission due to decompensated heart failure reduced by 50 per cent. A 77 per cent reduction in total hospital days saved for treating heart failure was observed in the CRT group compared with the control group. The COMPANION study (Bristow et al 2000) randomised more than 1,600 patients to medical treatment only, to CRT and to CRT with implantable cardiac defibrillators. This study had to be stopped part-way through because of a 20 per cent reduction in mortality and admission rates in the group with CRT. The group with the most notable benefit, receiving CRT with implantable cardiac defibrillators, showed a 40 per cent reduction in all cause mortality. These preliminary data indicate the benefits CRT may have on mortality. Possible limitations within this research have to be acknowledged. Many trials have a small sample size, which may undermine the external validity of the findings. Trial populations differ from those in clinical practice, for example, older patients and patients with co-morbidities are not well represented, leaving a gap in the evidence. There also appears to be limited follow-up to most trials. However, with the ongoing increase in CRT systems being fitted each year, future studies may be able to provide more answers and guidance for practice.
Psychological considerations
Many patients do not receive adequate psychological support before implantation of implantable cardioverter defibrillators (ICD) (Tagney 2004). The absence of support is compounded in patients with heart failure who already require a great deal of psychological support from nursing and medical teams within a hospital setting and in primary care due to the poor long-term prognosis of the disease. NICE (2000) acknowledges that implantation and activation of an ICD can cause adverse psychological impact, and calls for psychological preparation for patients living with an ICD. However, it does not suggest how NURSING STANDARD
this preparation should be conducted, or how healthcare professionals should be trained to provide such a service.
care for patients treated with CRT. However, Tagney et al (2003) suggest that nurses abilities to provide skilled, evidence-based information and care have been assumed, not assured by training, highlighting relevant educational needs within this field. Good communication skills are essential to assist patients in coming to terms with their situation. Further nursing research is required in this field so that nurses can improve their knowledge. Approaches to improving patient care could include study days, development of information packs and closer collaboration with specialist centres. This will enable nursing staff to inform patients and provide better understanding and support.
Limitations
Suitability and symptoms There are many factors to consider when a patient is referred for CRT, such as systolic heart failure, non-reversible cause, NYHA class III or IV, and optimal drug therapy. Echocardiography is the main tool used for predicting ventricular dyssynchrony and hence suitability for CRT. Up to 20 per cent of patients with heart failure who fulfil the criteria for CRT show little or no clinical benefit from resychronisation (Reuter et al 2002). With this in mind, medical staff may need more sensitive screening tools when assessing patients suitability for CRT. This could include tissue Doppler echocardiography, which allows quantification of dyssynchrony and provides a more accurate prediction of how patients would respond to resynchronisation therapy. It is important to acknowledge that patients, nurses and even medical staff are often unsure of the mechanisms of dyspnoea and there are likely to be many contributing factors to dyspnoea, many of which are not completely understood at present. Some conditions related to heart failure will almost certainly be irreversible, for example, pulmonary hypertension. Therefore, it is not surprising that CRT may not provide symptom improvement for all patients with heart failure. Left ventricular lead placement It is widely acknowledged that there are technical and anatomical problems when placing the left ventricular lead (Daubert et al 1998, Cazeau et al 2001). Eight per cent of procedures result in implant failures (Abraham et al 2002). Nearly all of these failures are caused by the inability to deploy the left ventricular lead (Abraham et al 2002), including the inability to intubate the coronary sinus, dissection of the coronary sinus, displacement of the left ventricular lead, and diaphragmatic stimulation. Most of the problems are reduced by the operators july 20 :: vol 19 no 45 :: 2005 49
&
Conclusion
The subject of CRT is discussed at cardiology conferences worldwide. Research trials and the money currently being invested in providing this treatment, mean that CRT will be a major treatment for patients with heart failure in the future. Although the device in the UK is about twice as expensive as a standard dual chamber system, repeated trials highlight the reduction in hospital admissions due to decompensating episodes of heart failure (Bristow et al 2000, Cazeau et al 2001, Abraham et al 2002). Growth in this technology will have economic implications for those planning and delivering health care. Research on the treatment of heart failure shows that medication, such as beta-blockers and ACE inhibitors (CONSENSUS Trial Study Group 1987, MERIT-HF Study Group 1999, Segev and Mekori 1999), and certain systems of care, such
as the introduction of heart failure nurse specialists (NICE 2003), reduce hospital admissions and are therefore cost effective. It could also be argued that, as CRT is a relatively new treatment for heart failure, this analysis of true cost effectiveness has not been proven. Furthermore, it is uncertain whether CRT is equally cost effective for all patients. Future research needs to determine whether CRT is less, equal or more effective than medication and/or care provision by specialist nurses. If there are 900,000 patients in the UK with heart failure, and up to 30 per cent have wide QRS complexes on ECG, then up to 300,000 patients may need to be considered for CRT. The resources needed to meet those demands are immense and the demographics of heart failure should also be considered. CRT techniques are becoming more effective with advancements in equipment, facilities and expertise. However, effects on mortality will not be fully determined until further trials are completed. Nurses need to develop their skills and knowledge to provide adequate patient support during informed decision-making regarding CRT and when providing care following resynchronisation NS
References
Abraham WT, Fisher WG, Smith AL et al (2002) Cardiac resynchronization in chronic heart failure. New England Journal of Medicine. 346, 24, 1845-1853. Bristow MR, Feldman AM, Saxon LA (2000) Heart failure management using implantable devices for ventricular resynchronisation: Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION steering committee and COMPANION Clinical Investigators. Journal of Cardiology Failure. 6, 3, 276-285. Cazeau S, Leclercq C, Lavergne T et al (2001) Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. The Multisite Stimulation in Cardiomyopathies study. New England Journal of Medicine. 344, 12, 873-880. CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine. 316, 23, 1429-1435. Cowie MR, Wood DA, Coats AJ et al (1999) Incidence and aetiology of heart failure; a population-based study. European Heart Journal. 20, 6, 421-428. Cowie MR, Wood DA, Coats AJ et al (2000) Survival of patients with new diagnosis of heart failure: a population based study. Heart. 83, 5, 505-510. Criteria Committee of the New York Heart Association (1994) Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Ninth edition. Little, Brown & Co, Boston MA. Curry CW, Nelson GS, Wyman BT et al (2000) Mechanical dyssynchrony in dilated cardiomyopathy with interventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. Circulation. 101, 1, e2. Daubert JC, Ritter P, Le Breton H et al (1998) Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing and Clinical Electrophysiology. 21, 1 Pt 2, 239-245. Davis RC, Hobbs FDR, Yip GY (2000) ABC of heart failure: history and epidemiology. British Medical Journal. 320, 7226, 39-42. Dougherty CM, Benoliel JQ, Bellin C (2000) Domains of nursing intervention after sudden cardiac arrest and automatic internal cardioverter defibrillator implantation. Heart and Lung. 29, 2, 79-86. Etienne Y, Mansourati J, Touiza A et al (2001) Evaluation of left ventricular function and mitral regurgitation during left ventricularbased pacing in patients with heart failure. European Journal of Heart Failure. 3, 4, 441-447. Gold MR, Feliciano Z, Gottlieb SS, Fisher ML (1995) Dual-chamber pacing with a short atrioventricul delay in congestive heart failure: a randomised study. Journal of American Cardiology. 26, 4, 967-973. Linde C, Gadler F, Edner M, Norlander R, Rosenqvist M, Ryden L (1995) Results of atrioventricular synchronous pacing with optimised delay in patients with severe congestive heart failure. American Journal of Cardiology. 75, 14, 919-923. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353, 9169, 2001-2007. National Institute for Health and Clinical Excellence (2000) Guidance on the Use of Implantable Cardioverter Defibrillators for Arrhythmias. NICE, London. National Institute for Health and Clinical Excellence (2003) Chronic Heart Failure. Management of Chronic Heart Failure in Adults in Primary and Secondary Care. Clinical Guideline 5. NICE, London. Reuter S, Garrigue S, Barold SS et al (2002) Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. American Journal of Cardiology. 89, 3, 346-350. Segev A, Mekori YA (1999) The Cardiac Insufficiency Bisoprolol Study II. Lancet. 353, 9161, 1361. Tagney J (2004) Can nurses in cardiology areas prepare patients for implantable cardioverter defibrillator implant and life at home. Nursing in Critial Care. 9, 3, 104-114. Tagney J, James JE, Albarran JW (2003) Exploring the patients experiences of learning to live with an implantable cardioverter defibrillator from one UK centre: a qualitative study. European Journal of Cardiovascular Nursing. 2, 3, 195-203.
NURSING STANDARD